Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation

BACKGROUND: Cyclic-dependent kinase (CDK) 4/6 kinases, as the critical drivers of the cell cycle, are involved in the tumor progression of various malignancies. Pharmacologic inhibitors of CDK4/6 have shown significant clinical prospects in treating hormone receptor-positive and human epidermal grow...

Descripción completa

Detalles Bibliográficos
Autores principales: Quan, Chuntao, Wu, Zhijie, Xiong, Juan, Li, Manqing, Fu, Yu, Su, Jiaying, Wang, Yue, Ning, Lvwen, Zhang, Deju, Xie, Ni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687910/
https://www.ncbi.nlm.nih.gov/pubmed/38037159
http://dx.doi.org/10.1186/s40164-023-00462-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687910/
https://www.ncbi.nlm.nih.gov/pubmed/38037159
http://dx.doi.org/10.1186/s40164-023-00462-7

Ejemplares similares